1. Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Issue 24 (25th September 2020) Authors: Feldman, Darren R.; Ged, Yasser; Lee, Chung‐Han; Knezevic, Andrea; Molina, Ana M.; Chen, Ying‐Bei; Chaim, Joshua; Coskey, Devyn T.; Murray, Samuel; Tickoo, Satish K.; Reuter, Victor E.; Patil, Sujata; Xiao, Han; Aghalar, Jahan; Apollo, Arlyn J.; Carlo, Maria I.; Motzer, Robert J.; Voss, Martin H. Journal: Cancer Issue: Volume 126:Issue 24(2020) Page Start: 5247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗